Thomas A. Hensing, MD
The treatment of patients with stage III non–small cell lung cancer (NSCLC) requires a more personalized approach and newer technology, says Thomas A. Hensing, MD.
Additionally, Hensing stressed that to avoid the one-size-fits-all approach that once hindered progress in stage IV disease management, modern technology and novel therapeutics not only need to be adopted, but must be managed by a multidisciplinary team to achieve optimal outcome for patients with stage III NSCLC.
OncLive: Please provide an overview of your talk.
: Basically, the premise of my talk is that we have really had a prolonged plateau in outcomes for patients with stage III NSCLC. That is because we are approaching the management of stage III disease as we used to approach the management of stage IV disease, which is a sort of one-size-fits-all approach. We haven’t yet applied what we’ve learned in the management of stage IV disease into the stage III or curative setting, but that is starting to change.
... to read the full story